• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

    7/23/26 3:09:13 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNTA alert in real time by email

    MILAN and NAPLES, Italy, July 23, 2026 (GLOBE NEWSWIRE) -- Sòphia High Tech S.r.l. (Sòphia HT), an Italian aerospace and defense company manufacturing critical parts for Europe's space and defense programs, backed by Genenta Science S.p.A. (NASDAQ:GNTA) — evolving into Saentra Forge¹, a strategic industrial consolidator focused on aerospace, defense, biotech and Italian national-security-related technologies — today announced the unveiling of ROMAN, a robotic arm engineered to perform inspection and maintenance operations inside a nuclear fusion machine. Sòphia HT and its partners Department of Industrial Engineering (DII) and Herobots designed, developed, produced, assembled, tested and integrated the manipulator ROMAN units for two facilities: the DII of the University Federico II and to Consorzio RFX2.

    ROMAN demonstrates Sòphia HT’s ability to engineer systems for environments where humans cannot operate and failure is not an option. Designed for RFX-mod2, a nuclear fusion research machine in which plasma can reach approximately 20 million °C, ROMAN remotely inspects and maintains the machine’s innermost wall. Its custom-built tool can identify, remove and reinstall individual graphite tiles, as well as perform visual inspection and cleaning operations.

    ROMAN is the result of a close collaboration between Sòphia HT, Herobots – a technology partner specialized in robotics and automation for safety-critical applications – the DII and Consorzio RFX. Within the project, Sòphia HT led the development, manufacturing, assembly, testing, and integration of the ROMAN manipulators, working closely with all partners throughout the definition, validation, and refinement of the solution. The partners worked closely throughout the definition, validation, and refinement of the solution.

    The project extends Sòphia HT’s proven precision-engineering capabilities—from critical components for rockets, satellites and defense systems—into nuclear technology and energy infrastructure, while leveraging the robotics expertise for hazardous and challenging environments of the DII and Herobots team. This provides Sòphia HT with a new strong reference capability for future applications in another highly regulated, mission-critical market and supports Genenta’s strategy of building an industrial platform across sectors central to national technological sovereignty.

    "Delivering with our partners ROMAN took Sòphia HT into the nuclear domain for the first time, and our team met that challenge with the same rigor we apply to space-flight hardware. Developing a manipulator that can operate safely and repeatably inside RFX-mod2 required custom mechanics, a purpose-built end-effector and extensive qualification. It is a proud milestone for our engineers and PhDs, and, together with Genenta, it opens a new avenue of growth for the company," said Domenico Borrelli, CTO of Sòphia HT.

    "ROMAN is exactly the kind of capability that makes Sòphia HT irreplaceable. The same mastery of precision mechanics that lets this company 3D-print flight-ready space hardware now allows it to manufacture the mechanical systems of advanced robotic platforms operating where no human can go — inside a nuclear fusion machine. It is a powerful demonstration of how deep-tech know-how developed for space and defense translates directly into the technologies that will underpin energy independence. This is the model we are building: keeping critical industrial know-how in Italy, and letting it compound across the sectors that define national economic security," said Pierluigi Paracchi, CEO of Genenta.

    1 The name change from Genenta Science S.p.A. to Saentra Forge S.p.A. is subject to shareholder approval.

    2 https://www.igi.cnr.it/en/about-us/

    About Genenta Science

    Genenta Science (NASDAQ:GNTA) is evolving into a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national security-regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology/biosecurity. Genenta holds a 19% equity interest in Sòphia High Tech and has an option to increase its ownership to 51% at a pre-agreed valuation.

    About Sòphia High Tech

    Sòphia High Tech S.r.l. is an Italian aerospace and defense engineering and manufacturing company, headquartered in Somma Vesuviana (Naples). At its core, Sòphia HT builds the critical mechanical components of space and defense systems — the precision parts that hold rockets together, protect satellites in orbit, and allow aircraft to perform under extreme stress. The company covers the entire product lifecycle, from initial concept design and computer simulation, through prototyping and manufacturing, all the way to final testing, assembly, and qualification for flight. What sets Sòphia HT apart is its mastery of advanced manufacturing techniques — including state-of-the-art metal 3D printing (Selective Laser Melting), CNC precision machining and multitasking, and the ability to work with some of the most demanding exotic materials in the industry, including titanium, Inconel, tungsten, and specialized copper alloys. Certified to the EN9100 aerospace quality standard and to ECSS-Q-ST-70-80C, the ESA specification for additive manufacturing, Sòphia HT is one of the very few companies in Europe qualified to 3D-print flight-ready space hardware to ESA and NASA standards. With over 530 advanced projects completed, Sòphia HT serves leading European aerospace and defense organizations, including ESA, AVIO, Thales Alenia Space, Leonardo, MBDA, GSSI, and D-Orbit.

    Forward-Looking Statements. Statements in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the transition to Saentra Forge, the expansion to a sovereign-aligned industrial consolidator. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Genenta's Annual Report on Form 20-F for the year ended December 31, 2025, and Genenta's material disclosures on Form 6-K dated October 10, 2025, January 26, 2026, as well as other Form 6-K disclosures filed with the Securities and Exchange Commission. Forward-looking statements contained in this document are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law.

    Genenta Science Media

    Tiziana Pollio, Mobile: +39 348 23 15 143

    email: tiziana.pollio@genenta.com



    Primary Logo

    Get the next $GNTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNTA

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

    MILAN and NAPLES, Italy, July 23, 2026 (GLOBE NEWSWIRE) -- Sòphia High Tech S.r.l. (Sòphia HT), an Italian aerospace and defense company manufacturing critical parts for Europe's space and defense programs, backed by Genenta Science S.p.A. (NASDAQ:GNTA) — evolving into Saentra Forge¹, a strategic industrial consolidator focused on aerospace, defense, biotech and Italian national-security-related technologies — today announced the unveiling of ROMAN, a robotic arm engineered to perform inspection and maintenance operations inside a nuclear fusion machine. Sòphia HT and its partners Department of Industrial Engineering (DII) and Herobots designed, developed, produced, assembled, tested and i

    7/23/26 3:09:13 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

    Fiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of production increased 34.7% to €8.47 millionEBITDA grew 68.1% to €1.61 million, expanding the EBITDA margin by approximately 380 basis points to 19.0%Operating profit advanced 80.8% to €1.21 million MILAN, July 22, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on aerospace, defense, biotech and Italian national-security-related technologies, today announced that the Board of Directors of Sòphia High Tech S.r.l. ("Sòphia HT") has approved the company’s financial statements for the fiscal year ended December 31, 2025.

    7/22/26 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta signs Definitive Agreements with Sophia High Tech

    MILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has signed definitive agreements2 with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs. Genenta expects to fund a total of €6.0 million in two tranches. With the closing of the first tranche, Genenta will obtain a 19.9% stake, and with the closing of the second tranche, Genenta will own a 51% stake in Sòphia HT. The proceeds are expected to be deploy

    4/23/26 7:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    SEC Filings

    View All

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    7/14/26 4:04:57 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    7/1/26 4:09:58 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    6/26/26 4:05:24 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

    ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

    6/29/23 9:11:48 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

    H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

    7/25/22 7:15:53 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Paracchi Pierluigi

    4 - Genenta Science S.p.A. (0001838716) (Issuer)

    5/5/26 9:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Paracchi Giacomoantonio

    4 - Genenta Science S.p.A. (0001838716) (Issuer)

    4/1/26 4:05:24 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Galimi Francesco

    4 - Genenta Science S.p.A. (0001838716) (Issuer)

    4/1/26 4:05:27 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Leadership Updates

    Live Leadership Updates

    View All

    Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

    MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) in transformation to Saentra Forge (NASDAQ:SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry into defense technology manufacturing. The Company also provided an update on its ongoing evaluation of majority-control acquisition opportunities in regulated national-security sectors. Mr. Salvato previously served as Chief Executive Officer of Fiocchi Munizioni S.p.A. (CSG Group

    2/27/26 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

    Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

    1/8/25 3:17:00 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

    MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

    5/6/24 6:25:00 AM ET
    $ARYD
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

    2/12/24 4:05:34 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

    2/10/23 6:02:50 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Genenta Science S.p.A.

    SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

    2/25/22 1:17:49 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care